Search

Products derived from embryonic stem cells are not patentable

Therapies based on human embryonic stem cells should not be granted patents, according to the latest opinion from the Court of Justice of the European Union. If confirmed, this will have a major impact on stem cell research in Europe and on the European life sciences industry as a whole

The difficulties of energy R&D

Memo to governments: Energy research is different than that in other sectors – longer term, more costly, higher hurdles to market.

Maybe Europe’s pharma sector can save itself

As the second tranche of projects in the €2 billion Innovative Medicines Initiative was announced this week, a quick stock take of progress to date hints at what this wide-ranging collaboration could deliver